Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06599229

Perfusion Abnormalities in Hypertrophic Cardiomyopathy

The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Hypertrophic Cardiomyopathy (HCM) Aortic Stenosis, Subvalvular Aortic Valve Disease Aortic Valve Stenosis Cardiomyopathies Cardiomyopathy, Hypertrophic Cardiovascular Diseases Heart Diseases Heart Valve Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Virginia

Charlottesville, Virginia, 22903, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of hypertrophic cardiomyopathy
  • Subject being initiated on clinically-indicated cardiac myosin inhibitor therapy

Exclusion criteria

  • Pregnancy
  • Lactation
  • Allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson
  • Serious AE to regadenoson
  • Hypotension
  • Serious bradycardia not addressed by pacemaker
  • Moderate or greater reactive airways disease

Treatment and study plan

myocardial contrast echo

Diagnostic Test

Vasodilator stress myocardial contrast echocardiography will be performed at baseline and within 4 months of reaching target dose of a cardiac myosin inhibitor.

Primary outcomes

  1. Peak hyperemic perfusion

    Time frame: 3 months

    Myocardial contrast echo-derived myocardial blood flow at peak hyperemia (produced by regadenoson)

Secondary outcomes

  1. Resting myocardial perfusion

    Time frame: 3 months

    Resting myocardial perfusion by MCE

Sponsors and collaborators

Lead sponsor

University of Virginia

Other

Registry information

Official study title

Myocardial Perfusion Abnormalities in Hypertrophic Cardiomyopathy

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 19, 2024
Registry last updated
Apr 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.